Mycosis fungoides – хистологични рискови фактори

  • Иван Киндеков
Keywords: Т-клетъчни лимфоми, Mycosis fungoides, хистологични рискови фактори

Abstract

Кожните лимфоми са хетерогенна група лимфопролиферативни неоплазии. По определение, първичните кожни лимфоми са екстранодални лимфоми с кожно засягане и понякога системно засягане при поставяне на диагнозата. Диагностичните критерии са добре дефинирани, но понякога диференциалната диагноза е широка. Mycosis fungoides е хематологична неоплазия, произлизаща от зрели неопластични Т-лимфоцити, които имат предилекционно ангажиране на кожата. По правило лимфомът се характеризира с индолентен ход, като симптомите на заболяването могат да проявят продължително време между 2 и 10 години. Прогнозата за пациента се определя най-вече от стадия на заболяването при дебюта, възрастта, хистологично доказаната едроклетъчна трансформация, LDH, които са независими рискови фактори за лоша прогноза. Хистологичната диагностика е важна при отдиференцирането на кожния Т-клетъчен лимфом от други доброкачествени индолентни състояния.

References

Fink-Puches R, Zenahlik P, Bäck B, et al. Primary cutaneous lymphomas: applicability of current classification schemes (European Organization for Research and Treatment of Cancer, World Health Organization) based on clinicopathologic features observed in a large group of patients. Blood. 2002;99(3):800-805.
Gilson D, Whittaker SJ, Child FJ, et al. British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guide-lines for the management of primary cutaneous lymphomas 2018. Br J Dermatol. 2019;180(3):496-526.
Olsen EA, Whittaker S, Willemze R, et al. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood. 2022;140(5):419-437.
Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. IARC Press; 2017.
Trautinger F, Eder J, Assaf C, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – update 2017. Eur J Cancer. 2017;77:57-74.
Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703-1714.
Sanchez JL, Ackerman AB. The patch stage of mycosis fungoides. Criteria for histologic diagnosis. Am J Dermatopathol. 1979 Spring;1(1):5-26.
Scarisbrick JJ, Morris S. How big is your hand and should you use it to score skin in cutaneous T-cell lymphoma? Br J Dermatol. 2013;169(2):260-265.
Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the international society for cutaneous lymphomas, the United States cutaneous lymphoma consortium, and the cutaneous lymphoma task force of the European organisation for Research and treatment of cancer. J Clin Oncol. 2011;29(18):2598-2607.
Bahalı AG, Su O, Cengiz FP, et al. Prognostic factors of patients with mycosis fungoides. Postepy Dermatol Alergol. 2020 Oct;37(5):796-799.
Cerroni L. Skin Lymphoma – The Illustrated Guide. 5th ed. Wiley Blackwell; 2020.
Cetinozman F, Jansen PM, Willemze R. Expression of programmed death-1 in skin biopsies of benign inflammatory vs. lymphomatous erythroderma. Br J Dermatol. 2014;171(3):499-504.
Diamandidou E, Colome M, Fayad L, et al. Prognostic factor analysis in mycosis fungoides/Sézary syndrome. J Am Acad Dermatol. 1999 Jun;40(6 Pt 1):914-24.
Massone C, Kodama K, Kerl H, et al. Histopathologic features of early (patch) lesions of mycosis fungoides. A morphologic study on 745 biopsy specimens from 427 patients. Am J Surg Pathol. 2005;29(4):550-560.
Pimpinelli N, Olsen EA, Santucci M, et al; International Society for Cutaneous Lymphoma. Defining early mycosis fungoides. J Am Acad Dermatol. 2005 Dec;53(6):1053-63.
Salhany KE, Cousar JB, Greer JP, et al. Transformation of cutaneous T cell lymphoma to large cell lymphoma. A clinicopathologic and immunologic study. Am J Pathol. 1988 Aug;132(2):265-77.
Scarisbrick JJ, Kim YH, Whittaker SJ, et al. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now? Br J Dermatol. 2014 Jun;170(6):1226-36.
Scarisbrick JJ, Prince HM, Vermeer MH, et al. Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and Sézary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol. 2015;33(32):3766-3773.
Scarisbrick JJ, Quaglino P, Prince HM, et al. The PROCLIPI inter-national registry of early-stage mycosis fungoides identifies sub-stantial diagnostic delay in most patients. Br J Dermatol. 2019;181(2):350-357.
Smoller BR, Bishop K, Glusac E, et al. Reassessment of histologic parameters in the diagnosis of mycosis fungoides. Am J Surg Pathol. 1995 Dec;19(12):1423-30.
Stevens SR, Ke MS, Parry EJ, et al. Quantifying skin tumour burden in mycosis fungoides. Arch Dermatol. 2002:42-48.
Vonderheid EC, Pavlov I, Delgado JC, et al. Prognostic factors and risk stratification in early mycosis fungoides. Leuk Lymphoma. 2014 Jan;55(1):44-50.
Published
2024-02-09
How to Cite
1.
Киндеков И. Mycosis fungoides – хистологични рискови фактори. Редки болести и лекарства сираци [Internet]. 2024Feb.9 [cited 2024Feb.29];14(3-4):7-. Available from: https://journal.raredis.org/index.php/RBLS/article/view/188
Section
Статии